Ultragenyx Pharmaceutical Inc [RARE] stock is trading at $39.29, up 4.75%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RARE shares have gain 6.45% over the last week, with a monthly amount glided 10.99%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Goldman upgraded its rating to Buy on June 06, 2024, and elevated its price target to $67. On April 22, 2024, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $77 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $72 on December 08, 2023. Evercore ISI upgraded its rating to Outperform for this stock on June 06, 2023, and upped its price target to $80. In a note dated April 26, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $114 on this stock.
Ultragenyx Pharmaceutical Inc [RARE] stock has fluctuated between $29.59 and $60.37 over the past year. Currently, Wall Street analysts expect the stock to reach $89.5 within the next 12 months. Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] shares were valued at $39.29 at the most recent close of the market. An investor can expect a potential return of 127.79% based on the average RARE price forecast.
Analyzing the RARE fundamentals
Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] reported sales of 590.69M for the trailing twelve months, which represents a growth of 27.99%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.87%, Pretax Profit Margin comes in at -0.93%, and Net Profit Margin reading is -0.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -1.86 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Ultragenyx Pharmaceutical Inc’s Current Ratio is 2.40. As well, the Quick Ratio is 2.24, while the Cash Ratio is 0.44. Considering the valuation of this stock, the price to sales ratio is 6.29, the price to book ratio is 25.53.
Transactions by insiders
Recent insider trading involved Crombez Eric, EVP and Chief Medical Officer, that happened on May 05 ’25 when 520.0 shares were sold. EVP and Chief Medical Officer, Crombez Eric completed a deal on Apr 21 ’25 to sell 242.0 shares. Meanwhile, Chief Financial Officer Horn Howard sold 1785.0 shares on Mar 06 ’25.
